⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Official Title: Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.

Study ID: NCT02572843

Study Description

Brief Summary: The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary resectable stage IIIA(N2) NSCLC is efficacious and feasible.

Detailed Description: Despite multimodal therapy, the cure rate of patients with stage IIIA NSCLC is poor and therapy outcome failed to improve during the past years. The addition of immunotherapy with the anti-PD-L1 antibody MEDI4736 as a novel treatment modality has the potential to improve the outcome without adding substantial toxicity to an otherwise intensive multimodality treatment, as MEDI4736 has been generally well tolerated. Based on the current evidence on immune checkpoint inhibition, there is a strong rationale to test this novel treatment modality also in the curative setting in order to improve local tumor control and prevent distant metastasis to improve the cure rate in this patient population. The trial investigates the addition of pre- and post-operative immune checkpoint inhibition with MEDI4736 to the previously established standard of care for stage IIIA(N2) patients, which is based on the trials SAKK16/96 and SAKK16/00. Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin (100 mg/m2) / docetaxel (85 mg/m2), followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Stadtspital Triemli, Zürich, Zurich, Switzerland

Kantonsspital Aarau, Aarau, , Switzerland

Kantonsspital Baden, Baden, , Switzerland

St. Claraspital Basel, Basel, , Switzerland

Universitaetsspital Basel, Basel, , Switzerland

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, , Switzerland

Inselspital Bern, Bern, , Switzerland

Kantonsspital Graubuenden, Chur, , Switzerland

Spital Thurgau AG, Frauenfeld, , Switzerland

Hopital Fribourgeois HFR, Fribourg, , Switzerland

Hopital Cantonal Universitaire de Geneve, Geneva, , Switzerland

CCAC Lausanne, Lausanne, , Switzerland

Centre hospitalier universitaire vaudois CHUV, Lausanne, , Switzerland

Luzerner Kantonsspital, Luzern, , Switzerland

Kantonsspital St. Gallen, St. Gallen, , Switzerland

Regionalspital, Thun, , Switzerland

Kantonsspital Winterthur, Winterthur, , Switzerland

Klinik Hirslanden Onkozentrum Zürich, Zurich, , Switzerland

UniversitaetsSpital Zuerich, Zurich, , Switzerland

Contact Details

Name: Sacha Rothschild, MD, PhD

Affiliation: University Hospital, Basel, Switzerland

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: